Known safety concerns, contraindications, and risk factors.
This protocol describes peptides currently in clinical investigation for cardiovascular indications. None are FDA-approved for cardiovascular use. This is educational synthesis, not medical advice. Any therapeutic decision must involve a qualified clinician, ideally a cardiologist familiar with the specific compound's trial history and your individual cardiovascular status.
Acute myocardial infarction with Killip ≥III
Excluded from cardiac peptide trials — insufficient human evidence for safety in decompensated cardiac patients.
Active or recent malignancy
Pro-angiogenic peptides theoretically feed occult tumours.
Severe hepatic or renal dysfunction
Altered peptide metabolism and clearance; uncharacterised pharmacokinetics.
Pregnancy or lactation
No safety data in pregnancy or lactation for any peptide in this protocol.
Pediatric populations
No safety or efficacy data in children or adolescents for cardiovascular peptide indications.